In an adult patient with a light growth of Klebsiella pneumoniae that is intermediate to piperacillin but susceptible to ceftriaxone, and who is clinically stable with normal renal function, should therapy be stepped down to ceftriaxone?

Yes, step down to ceftriaxone for this Klebsiella infection

In a clinically stable patient with light growth of Klebsiella that is susceptible to ceftriaxone, you should step down from piperacillin to ceftriaxone, even though the isolate shows intermediate susceptibility to piperacillin. This represents appropriate antimicrobial stewardship by narrowing to the most targeted effective agent.

Rationale for Stepping Down

The key principle here is treating based on demonstrated susceptibility rather than the initial empiric regimen. When an organism shows susceptibility to ceftriaxone, this becomes your preferred definitive therapy for several reasons:

• Ceftriaxone is highly effective against ceftriaxone-susceptible Klebsiella, regardless of piperacillin susceptibility status 1
• Intermediate susceptibility to piperacillin is clinically irrelevant when you have a fully susceptible alternative
• Recent evidence specifically addresses this scenario: A 2024 study demonstrated that ceftriaxone effectively treats bloodstream infections with E. coli or K. pneumoniae that are piperacillin/tazobactam-non-susceptible but ceftriaxone-susceptible, with no difference in 90-day mortality, readmission, or recurrence compared to alternative antibiotics 1

Clinical Evidence Supporting This Approach

The epidemiologic data shows this susceptibility pattern (piperacillin-resistant but ceftriaxone-susceptible) occurs in approximately 4% of Enterobacteriaceae bacteremias 2. These isolates typically harbor TEM-1 or SHV-1 β-lactamases but lack ESBLs or AmpC enzymes 2. Importantly:

• 30-day mortality with ceftriaxone therapy was 25%, comparable to broader-spectrum alternatives 2
• Targeted cephalosporin therapy did not yield higher mortality than carbapenem therapy 2
• The Bayesian analysis showed 85% posterior probability that ceftriaxone is as good or better than alternative therapy 1

Practical Implementation

Switch to ceftriaxone 2 grams IV every 12-24 hours (depending on infection severity and site). For most non-CNS Klebsiella infections, once-daily dosing is adequate 3.

Important Caveats

• Ensure clinical stability first: Patient should be afebrile, hemodynamically stable, with improving inflammatory markers
• Verify normal renal function: Ceftriaxone dosing doesn't require adjustment for renal impairment alone, but monitor for biliary complications 4
• Consider infection source: For severe infections (bacteremia, pneumonia), continue for appropriate duration (typically 7-14 days for bacteremia, 14 days for pneumonia) 5, 6
• Monitor for treatment failure: If clinical deterioration occurs within 48-72 hours, reassess susceptibilities and consider broader coverage

Specific Warnings with Ceftriaxone

Be aware that ceftriaxone can cause:

• Gallbladder pseudolithiasis (ceftriaxone-calcium precipitates appearing as sludge on ultrasound) 4
• Urolithiasis and post-renal acute kidney injury (ensure adequate hydration) 4
• Prothrombin time alterations (monitor in patients with hepatic disease or malnutrition) 4

Why Not Continue Piperacillin?

Intermediate susceptibility means unpredictable clinical response. The MIC falls in a gray zone where standard dosing may not achieve adequate drug concentrations at the infection site. Using a fully susceptible agent eliminates this uncertainty and represents better antimicrobial stewardship by avoiding unnecessarily broad coverage.

The "light growth" mentioned in your question actually supports stepping down - lower bacterial burden typically responds better to narrower-spectrum agents, and you want to minimize selection pressure for resistance.